Drug Profile


Alternative Names: EMD-61753; EMR 63 320; ONO-3951

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck KGaA
  • Developer Merck KGaA; Ono Pharmaceutical; Tioga Pharmaceuticals
  • Class Acetamides; Opioid analgesics; Pyrrolidines; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pruritus
  • Discontinued Irritable bowel syndrome; Pain; Postoperative ileus

Most Recent Events

  • 06 Aug 2015 Discontinued - Phase-III for Irritable bowel syndrome in USA (PO)
  • 01 Jun 2015 Phase-II clinical trials in Pruritus in USA (PO)
  • 01 Jun 2013 Tioga Pharmaceuticals completes a phase III in Irritable bowel syndrome (diarrhoea-predominant) in USA (NCT01100684)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top